Immune therapy of lupus: What is on the horizon?

Nephrology Dialysis Transplantation

Volumn 21, Issue 3, 2006, Pages 579-581

  Navarra, Sandra V ^a  

^a UNIVERSITY OF SANTO TOMAS   (Philippines)

Author keywords

Anti cytokine; Immunotherapy; Lupus nephritis; Monoclonal antibodies; Treatment

Indexed keywords

ABATACEPT; ABETIMUS; B7 ANTIGEN; BELIMUMAB; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPRATUZUMAB; GAMMA INTERFERON; IDEC 131; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR;

ADJUVANT THERAPY; B LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH2 CELL; THROMBOSIS;

ANIMALS; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 33644866316     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi282     Document Type: Editorial

References (37)

1. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481-490
2. Vasoo S, Hughes GRV. Theory, targets and therapy in systemic lupus erythematosus. Lupus 2005; 14: 181-188
3. Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus 2005; 14: 13-18
4. Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988; 141: 3050-3054
5. Malide D, Russo P. Bendayan M. Presence of tumor necrosis factor-alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995; 26: 558-564
6. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067-1074
7. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open label study. Arthritis Rheum 2004; 50: 3161-3169
8. Faust J, Menke J, Kriegsmann J et al. Correlation of renal tubular epithelial cell-derived interleukin-18 upregulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Arthritis Rheum 2002; 46: 3083-3095
9. Schmidt KN, Ouyang W. Targeting interferon-alpha in SLE therapy. Lupus 2004; 13: 348-352
10. Santiago-Raber ML, Baccala R, Haraldsson KN et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-788
11. Mihara M, Takagi N, Takeda Y, Obsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Rheumatol 1998; 112: 397-402
12. Tackey E. Lipsky PE, Illei G. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13: 339-343
13. Park Y. Lee SK, Kim DS et al. Elevated IL-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 283-288
14. Llorente L, Richard-Patin Y, Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin 10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1790-1800
15. Anolik J, Sanz I. B cells in human and murine systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16: 505-512
16. Chan OT, Hannum LG, Haberman AM et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-1648
17. Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 1994; 152: 1453-1461
18. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589
19. Leandro MJ, Edwards JC, Cambridge G et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677
20. Leandro MJ, Ehrenstein MR, Edwards JC et al. Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum 2003; 48: S594
21. Boletis JN, Sfikakis PP, Lionaki SJ et al. An open study of B cell depletion in patients with proliferative lupus nephritis: Preliminary results. J Am Soc Nephrol 2003; 14: 379
22. Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590
23. Tahir H, Isenberg DA. Novel therapies in lupus nephritis. Lupus 2005; 14: 77-82
24. Kaufmann J, Wegener WA, Horak ID et al. Initial clinical study of immunotherapy in SLE using epratuzumab (humanized anti-CD22 antibody). Arthritis Rheum 2004; 50: S447
25. Jones DS, Barstad PA, Field MJ et al. Immunospecific reduction of antioligonucleotide antibody forming cells with a tetrakis-oligonucleotide conjugate (LJP-394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem 1995; 38: 2138-2144
26. Weisman MH, Bluestein HG, Berner CM et al. Reduction in circulating dsDNA antibody titre after administration of LJP-394. J Rheumatol 1997; 24: 314-318
27. Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP-394 for the prevention of renal flare in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 442-454
28. Zhang J, Roschke V, Baker KP et al. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10
29. Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum 2003; 48: 3475-3486
30. Furie R, Stohl W, Ginzler E et al. Safety, pharmacokinetic and pharmacodynamic results of a phase I single and double dose-escalation study of lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 2003; 48: S377
31. Crow M. Costimulatory molecules and T cell-B cell interactions. Rheum Dis Clin N Am 2004; 30: 175-192
32. Wang X, Huang W, Schiffer LE et al. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 2003; 48: 495-506
33. Kalunian KC, Davis Jr. JC, Merrill JT et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 3251-3258
34. Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-727
35. Reynolds J, Tam FW, Chandraker A et al. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest 2000; 105: 643-651
36. Daikh DI, Wofsky D. Reversal of advanced murine lupus nephritis with combined CTLA4Ig and cyclophosphamide. Arthritis Rheum 1996; 39: S140
37. Ruderman EM, Pope RM. The evolving clinical profile of abatacept (CTLA4-Ig): A novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther 2005; 7 [Suppl 2]: S21-S25